Adjuvant Data in Combination with Antigen Data. Subject to Genocea’s prior written consent, which is not to be unreasonably withheld or delayed, Isconova shall have the right to include data which both (i) arises from Development activities performed under this Agreement and (ii) relates to the Licensed Adjuvant in any Drug Master File Isconova may file with either the FDA or other Regulatory Authorities; provided, however, that in no event shall the data included in a Drug Master File pursuant to this Section 3.2.3 include identifying characteristics of any Genocea Antigens and that, furthermore, Genocea shall have the right to review such filings prior to their submission and redact any antigen-related information from the data prior to its disclosure to Isconova under this Section 3.2.3.
Appears in 4 contracts
Samples: License and Collaboration Agreement (Genocea Biosciences, Inc.), License and Collaboration Agreement (Genocea Biosciences, Inc.), License and Collaboration Agreement (Genocea Biosciences, Inc.)
